Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward in expanding access to ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

Omnipod 5 will be accessible in Belgium in the coming weeks, with Abbott's FreeStyle Libre 2 Plus and Dexcom G6 and G7 sensor integrations. Omnipod 5 will next launch in Canada later this spring with ...

Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...